Connecting Innovation to Purpose
Padcev® projected to reach up to ~$5B in global sales by 2028
6
L
PADCEV.
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials
Latest Padcev® 03 revenues ¹
1
(dollars in millions)
Total Net Product Sales
ADCETRIS
PADCEV
TUKYSA
TIVDAK
Ⓡ
Three months ended September 30,
2022
2023
% Change
$ 571
$ 428
33
$ 246
$ 219
13
$ 200
$ 105
89
$ 102 $ 88
$ 23 $ 16
16
40
%
%
%
%
%
Nine months ended September 30,
% Change
27
25
2023
$ 1,583
$ 751
$ 479
$ 289
$ 64
2022
$ 1,243
$ 601
$ 329
$ 267
$ 45
46
Sources: 1. SGEN Q3 earnings report, 2. SGEN press release, October 2023, 3. Evaluate Pharma
8
42
%
%
%
%
%
22nd October 2023 ²
Groundbreaking EV-302 Trial Significantly Extends Overall
Survival and Progression-Free Survival in Patients Treated
with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDAⓇ
(pembrolizumab) in First-Line Advanced Bladder Cancer
2021
PADCEVⓇ Global Projected Revenues in
UC/Bladder³
$5B
2022 2023 2024 2025
2026
2027 2028View entire presentation